

**Nov 5, 2015**

THU 0800-1815

**Nov 6, 2015**

FRI 0830-1330

Child & Family Research Institute  
Chan Auditorium  
950 West 28th Ave  
Vancouver, BC V5Z 4H4

# VACCINOLOGY RESEARCH SYMPOSIUM

In celebration of Dr. David Scheifele's Research Career

## INFORMATION

This Vaccinology Research Symposium is being held to celebrate the outstanding research career of Dr. David Scheifele. For more than 35 years he has dedicated his career to improving health through prevention of infections.

## WHO SHOULD ATTEND

All individuals involved in immunization from research to front line provisions, which may include:

- Public health physicians
- Infectious disease physicians
- Public health immunization program managers
- Microbiologists
- Immunologists & epidemiologists

## CALL FOR ABSTRACTS!

Abstracts are being accepted. For more information visit [www.caire.ca](http://www.caire.ca)

You can participate in person or via web-cast.

Registration is free but limited.

Visit: [www.caire.ca](http://www.caire.ca)

**Continuing Medical Education  
MOC Section 1: up to 7.0 credits**

Accredited by UBC CPD



CONTINUING PROFESSIONAL DEVELOPMENT  
FACULTY OF MEDICINE

## Topics to be covered

- 1 Pneumococcal & Meningococcal Conjugate Vaccines
- 2 Vaccine Preventable Disease Surveillance
- 3 Measles Elimination
- 4 New Vaccines for Enteric Diseases & Group A Streptococcus
- 5 Zoster Vaccine
- 6 Vaccine Research for Emergencies
- 7 Pertussis Control
- 8 Advances in Vaccine Development
- 9 Vaccine Safety

## Panel Discussions

- 1 The challenges of translating research into action
- 2 Looking to the future: Next decade of research priorities for immunization



Department of  
Pediatrics  
Division of  
Infectious  
Diseases

# Vaccinology Research Symposium

Thursday, November 5, 2015 Chan Auditorium, CFRI		
0800-0900	Registration	
<b>Session 1. Moderator – David Speert</b>		
0900-0915	Welcome & Symposium Objectives	David Speert University of BC, Canada
0915-0940	Pneumococcal conjugate vaccines: the multiple faces and influence on society Session learning objectives: 1. To review the different endpoints of pneumococcal vaccines. 2. To evaluate whether all pneumococcal vaccines are equal 3. To identify what other measurements of pneumococcal conjugated vaccine should be taken into account	David Greenberg Ben-Gurion University of Negev, Israel
0940-1005	Vaccine preventable diseases in Latin America and disease surveillance networks Session learning objectives: 1. To describe the impact of vaccine-preventable diseases and deaths in Latin American children 2. To review the obstacles and successes of vaccine introduction in developing countries: The Latin American experience 3. To review the Pediatric Infectious Diseases Collaborative Research Networks in Latin America	Rolando Ulloa-Gutierrez National Children's Hospital, Costa Rica
1005-1035	Measles elimination in Canada Session learning objectives: 1. To describe the epidemiology of measles in Canada since 1996 2. To review why measles outbreaks are on the increase 3. To gain insights into what measures are required to maintain elimination of measles	Gaston De Serres Laval University, Canada
1035-1100	<b>Break</b>	
<b>Session 2. Moderator – Ron Gold</b>		
1100-1125	Plague in Athens, isolation in New York, prison in Baltimore, fever in Kathmandu and my contribution to endangering our grandchildren 1. To review the important role of enteric fever in global health and the challenges for control 2. To update on current vaccine strategies 3. To gain insights from experimental medicine studies into pathophysiology and protection.	Andrew Pollard University of Oxford, UK
1125-1150	CANVAS the Canadian National Vaccine Safety Network Session learning objectives: 1. To describe the CANVAS network and its contribution to monitoring of vaccine safety in Canada. 2. To review the preliminary vaccine safety data for the 2015-2016 Influenza season	Julie Bettinger University of BC, Canada
1150-1215	Vaccine research emergencies Session learning objectives: 1. To update the vaccine research experience during the recent Ebola outbreak and ongoing pandemic preparedness from a Canadian public health perspective. 2. To describe the key ethical, regulatory, legal and clinical trial considerations for vaccine research in support of public health emergencies. 3. To review how we can use the experience gained to be more prepared for the future.	Theresa Tam Public Health Agency of Canada
1215-1230	Canada's role in Vaccine Safety: what more should be done? Session learning objectives: 1. To list the strengths and gaps in the current state of vaccine safety in Canada 2. To review the global nature of vaccine safety and the related implications for vaccine safety research	Barb Law  Pre-recorded presentation

	3. To list key ways in which research can improve vaccine safety in Canada and beyond	
1230-1310	<b>Lunch</b>	
	<b>Session 3. Moderator – Scott Halperin</b>	
1310-1430	<p>Panel Discussion: You have planned your research, you have the results, now what? The challenges of translating research into action</p> <ul style="list-style-type: none"> <li>Independent research results &amp; moving them into action; role of regulators</li> <li>Process of developing a Meningococcal B Immunization Policy in the UK</li> <li>Decision-makers role in translating research</li> </ul> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>To describe the regulatory environment for vaccine research</li> <li>To distinguish the challenges of using vaccines “off label” in public programs including convincing public health, front-line providers and the public</li> </ol>	<p>Simon Dobson University of BC, Canada</p> <p>Andrew Pollard University of Oxford, UK</p> <p>Gaston De Serres Laval University, Canada</p>
1430-1500	<b>Break</b>	
	<b>Session 4. Moderator – Soren Gantt</b>	
1500-1525	<p>Vaccination to prevent Herpes Zoster and Postherpetic Neuralgia</p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>To review the pathogenesis and epidemiology of herpes zoster and the need for a herpes zoster vaccine.</li> <li>To describe the design of the Shingles Prevention Study, the study results, and the nature of the live attenuated Oka zoster vaccine.</li> <li>To describe current recommendations for the use of live attenuated Oka zoster vaccines, and the pros and cons of a new investigational adjuvanted recombinant glycoprotein E vaccine.</li> </ol>	<p>Michael Oxman University of California, San Diego, USA</p>
1525-1545	Development of Heat Stable Vaccines	Arnold Smith
1545-1600	Rapid Adverse Event Following Immunization (AEFI) surveillance following a mass meningococcal B vaccine program in a university setting: a Canadian Immunization Research Network (CIRN) study	Joanne Langley Dalhousie University
1600-1615	Sustaining Protection against Hepatitis B from Infancy to Adulthood: Assessing the Case for a Booster Dose in Adolescence	Michelle Pinto University of BC
1615-1630	Evaluation of the outbreak response immunization in the control of pertussis	Alexander Doroshenko University of Alberta
1630-1645	Development of a glycoconjugate vaccine to combat disease caused by <i>Haemophilus influenzae</i> type A	Andrew Cox National Research Council, Canada
1645-1700	Development of engineered transferrin receptor-based antigens towards a novel vaccine against <i>Neisseria meningitidis</i>	Jamie Fegan University of Calgary
1700-1715	Parental vaccine hesitancy in Quebec (Canada)	Eve Dubé Institut national de santé publique du Québec
1715-1730	Post-partum vaccination promotion intervention improves vaccination during infancy	Thomas Lemaître University of Sherbrooke
1730-1745	Vaccine Coverage for Kindergarteners: An Analysis of School and Area Variation in Vancouver, British Columbia and Surrounding Communities	Richard Carpiano University of BC
1745-1800	Improving immunization coverage in the face of anti-vaccine sentiment	Meena Dawar Vancouver Coastal Health

**Friday, November 6, 2015 Chan Auditorium, CFRI**

0830-0930	<p><b>BCCH Grand Rounds: Advances in Vaccine Development: Perspectives from former trainees from the Division of Infectious Diseases</b></p> <p><b>Development of a novel Meningococcal B vaccine: from bench to a phase 1 trial and beyond</b></p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To describe the development of the novel MenB vaccine MenPF;</li> <li>2. To describe results of the phase I clinical trial – safety and immunogenicity;</li> <li>3. To discuss the role of gene expression analysis in vaccine design</li> </ol> <p><b>The challenges of developing a Group A Streptococcus Vaccine</b></p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To review the rationale and need for a vaccine against GAS</li> <li>2. To review the range of GAS vaccine candidates</li> <li>3. To describe the possible pathways for GAS vaccine development over the next decade</li> </ol>	<p>Manish Sadarangani University of Oxford, UK</p> <p>Andrew Steer University of Melbourne, Australia</p>
0930-1000	<b>Break</b>	
	<b>Session 5. Moderator – Arnold Smith</b>	
1000-1025	<p>Pertussis vaccines: changes needed to improve disease control</p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To describe the changing epidemiology of pertussis</li> <li>2. To review the role of current pertussis vaccines in the control/non-control of pertussis.</li> <li>3. To identify the barriers for development of improved pertussis vaccines</li> <li>4. To relate the role of surveillance systems in monitoring current and future control of pertussis by vaccination</li> </ol>	<p>Scott Halperin Dalhousie University, Canada</p>
1025-1050	<p>Targeting transcriptional regulators as a novel way to direct vaccine immune responses</p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To describe what transcriptional activators are</li> <li>2. To describe the role that certain transcriptional activators play in determining T cell responses</li> <li>3. To discuss the potential to target these molecules to direct vaccine-induced responses</li> </ol>	<p>Brian Ward McGill University, Canada</p>
1050-1115	<p>Non-specific effects of immunization – the BCG story</p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To describe the non-specific protection received against unrelated pathogens after immunization with BCG vaccine.</li> <li>2. To describe changes occurring in the infants' innate immune system when immunized with BCG.</li> <li>3. To discuss the potential role of BCG vaccine in infant immunization programs in lower and middle income countries.</li> </ol>	<p>Nigel Curtis University of Melbourne, Australia</p>
1115-1130	<b>Break</b>	
	<b>Session 6. Moderator – Simon Dobson</b>	
1130-1245	<p>Panel discussion: Looking to the future</p> <ul style="list-style-type: none"> <li>• Next decade of research priorities for childhood immunization</li> <li>• Next decade of research priorities for adult immunization</li> <li>• How to sustain relevant and meaningful vaccine research</li> </ul> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To describe what the research priorities for childhood immunization should be over the next decade</li> <li>2. To describe what the research priorities for adult immunization should be over the next decade</li> <li>3. To discuss what is needed for academic and public health researchers to conduct the necessary research</li> </ol>	<p>Manish Sadarangani University of Oxford, UK</p> <p>Brian Ward McGill University, Canada</p> <p>Scott Halperin Dalhousie University, Canada</p>

1245-1330	<p>Closing Remarks: In praise of vaccine research networks</p> <p>Session learning objectives:</p> <ol style="list-style-type: none"> <li>1. To describe the evolution of vaccine research networks in Canada</li> <li>2. To review the fundamental value of such networks</li> <li>3. To discuss strategies for sustaining vaccine research networks</li> </ol>	<p>David Scheifele University of BC, Canada</p>
-----------	--	---

